Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Finnex Pharmaceuticals First Quarter 2026 Earnings and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. I would now like to turn the conference over to Finnex Chief Financial Officer Robert Andrade. Please begin. Thank you, Operator. And good morning, everyone. Thank you for joining us. We are pleased to host Fennec Pharmaceuticals' first quarter 2026 earnings conference call today, during which we will review our financial results as well as provide a general business update. Joining me from Fennec this morning is our Chief Executive Officer and Board Member, Jeff Hackman. I am also pleased to welcome our Chief Commercial Officer, Terry Evans. who is joining our earnings call for the first time. Terry is a seasoned commercial and operations leader with a proven track record for delivering significant revenue growth and leading high-performing teams. Terry's industry experience spans all facets of commercial operations, including sales, sales management, operations, market access, trade, specialty pharmacy, and data analytics. He has more than 25 years of commercial leadership experience with companies including Curex Pharmaceuticals, Horizon Therapeutics, and Medicis. Since joining Fennec in the fourth quarter of 2024, Terry has played a pivotal role in reshaping and strengthening our commercial organization. He has helped to sharpen our execution, enhance our field presence, and position the team to capitalize on the opportunities ahead. Later in the call, Terry will speak to how recent effort...